Anti-ADAM-15 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibodies targeting ADAM-15 (Q13444), validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential
UniProt
Q13444
Size
100ug
Cat. #
RP1ADAM15

In stock

SKU
RP-ADAM15

Options

As low as: $130.00

Target Overview

ADAM-15 (Disintegrin and metalloproteinase domain-containing protein 15, UniProt Q13444) is an 863-amino acid transmembrane metalloproteinase (EC 3.4.24.-) belonging to the ADAM family of multi-domain proteins. Localized to the endomembrane system, ADAM-15 exhibits both gelatinolytic and collagenolytic activity through its catalytic metalloproteinase domain. The protein contains a disintegrin domain that mediates cell-cell and cell-matrix interactions, notably inhibiting beta-1 integrin-mediated adhesion and migration in airway smooth muscle cells. ADAM-15 cleaves substrates including E-cadherin in response to growth factor deprivation and plays documented roles in wound healing, glomerular cell migration, and pathological neovascularization. The cytoplasmic domain contributes to intracellular signaling, including modulation of ERK1/2 activity. Researchers study ADAM-15 in contexts of extracellular matrix remodeling, epithelial-mesenchymal interactions, tissue repair, and reproductive biology, where it may function in sperm maturation and fertilization.

Background

ADAM-15 functions as an active sheddase and adhesion modulator at sites of tissue remodeling and cell migration. Its metalloproteinase domain cleaves extracellular matrix components and cell surface proteins, while the disintegrin domain mediates both heterotypic intraepithelial cell/T-cell interactions and homotypic T-cell aggregation. The protein suppresses cell motility on fibronectin substrates, apparently by driving alpha-v/beta-1 integrin cell surface expression through ERK1/2 inactivation. During pathological processes, ADAM-15 participates in cartilage remodeling and neovascularization, making it relevant to osteoarthritis and tumor biology research. Recent studies have positioned ADAM-15 as a biomarker candidate across multiple cancer types. Junhui et al. (2026) demonstrated that ADAM-15 promotes hepatocellular carcinoma progression and metastasis through activation of the JNK/p38 signaling pathway, establishing a mechanistic link between metalloproteinase activity and tumor cell invasion. Guo et al. (2026) validated ADAM-15 as a pan-cancer prognostic biomarker with particular relevance to immunotherapy response in hepatocellular carcinoma and colorectal adenocarcinoma. Comprehensive analyses of extracellular matrix protease signatures in breast cancer have incorporated ADAM-15 transcript levels into survival prediction models, while Mendelian randomization studies have explored ADAM-15 as a potential druggable target in chronotype-associated breast cancer risk. Triple Point Biologics offers four rabbit polyclonal antibodies raised against the cytoplasmic domain of human ADAM-15. These reagents are validated for Western blot applications in human samples, providing tools for investigating ADAM-15 expression, localization, and regulation across tissue remodeling and disease contexts.

References

  1. Junhui X (2026) ADAM15 promotes the progression and metastasis of hepatocellular carcinoma by activating the JNK/p38 pathway. Sci Rep. PubMed · DOI
  2. Guo W et al (2026) ADAM15 Is a Potential Biomarker for Pan-Cancer Prognosis and Immunotherapy: Validation in HCC and COAD. IUBMB Life. PubMed · DOI
  3. Babas R et al (2026) Integrative Survival Prediction in Breast Cancer Using Extracellular Matrix Protease Transcript Signatures and Clinical Variables: A Machine Learning Approach. Cancers (Basel). PubMed · DOI
  4. Romanowicz A et al (2026) The Potential of A Disintegrin and Metalloproteinase (ADAM) Proteins as Clinically Relevant Biomarkers in Colorectal Cancer: A Comprehensive Analysis. Cancers (Basel). PubMed · DOI
  5. Luo S et al (2026) Identifying druggable proteins of the association of chronotype on breast cancer using Mendelian randomization. Commun Med (Lond). PubMed · DOI

Additional Specifications

Gene Symbol ADAM15
UniProt ID Q13444
Host Species Rabbit
Species Reactivity Validated- Human
Potential
Pack Size 100ug
Immunogen (Cytoplasmic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 718-863.
Immunogen (Propeptide domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 18-206.
Immunogen (Carboxy end Propeptide Domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 186-206.
Immunogen (Amino end Active ADAM-15)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 207-257.
Alternate Names ADAM15, ADAM 15, Disintegrin and metalloproteinase domain-containing protein 15, Metalloprotease RGD disintegrin protein, Metalloproteinase-like, disintegrin-like, and cysteine-rich protein 15, MDC-15, Metargidin, EC 3.4.24.-

Frequently Asked Questions

What molecular weight should I expect for ADAM-15 on a Western blot?

Full-length ADAM-15 (Q13444) is an 863-amino acid protein with a predicted molecular weight of approximately 93 kDa. On reducing SDS-PAGE, you will typically observe bands between 100-110 kDa due to post-translational glycosylation of the extracellular domains. ADAM-15 undergoes proteolytic processing, so you may also detect lower molecular weight fragments corresponding to shed ectodomains or C-terminal fragments, particularly in cell culture supernatants or tissue samples with high protease activity. Always include a positive control lysate from cells known to express ADAM-15, such as HeLa or A549 cells.

What dilution should I start with for ADAM-15 Western blot and IHC?

For Western blot, begin at 1:1000 dilution in blocking buffer containing 5% non-fat milk or BSA in TBST. This dilution has been validated with this rabbit polyclonal antibody. For immunohistochemistry on paraffin-embedded sections, a typical starting range is 1:100 to 1:200 following heat-induced epitope retrieval in citrate buffer, pH 6.0. Optimal dilution will depend on your tissue type, fixation time, and detection system sensitivity. We recommend titrating across a dilution series with your specific sample type, as metalloproteinase expression varies widely across tissues and cell lines.

Is this ADAM-15 antibody specific to human or does it cross-react with mouse and rat?

This antibody has been validated for reactivity with human ADAM-15. Cross-reactivity with mouse and rat orthologs is predicted based on sequence homology but has not been experimentally validated. Human ADAM-15 shares approximately 85% identity with mouse and rat orthologs across the immunogenic region. If you are working with rodent samples, we recommend treating this antibody as experimental for those species and including appropriate positive controls from human cells alongside your rodent samples to assess specific versus cross-reactive signal. Request validation data for non-human species if available.

Does ADAM-15 require reducing conditions for Western blot detection?

ADAM-15 is a type I transmembrane protein with multiple disulfide bonds in its extracellular disintegrin and cysteine-rich domains. For optimal detection of the full-length protein by Western blot, perform SDS-PAGE under reducing conditions with DTT or beta-mercaptoethanol in your sample buffer. Under non-reducing conditions, intramolecular disulfide bonds may mask epitopes or alter migration. If you are specifically studying oligomerization or disulfide-linked ADAM-15 complexes, run parallel reduced and non-reduced gels. Standard RIPA or Laemmli buffer with reducing agent is suitable for most applications.

What tissues or cell lines are good positive controls for ADAM-15 expression?

ADAM-15 is broadly expressed but levels vary substantially. HeLa cervical carcinoma, A549 lung adenocarcinoma, and HEK293 cells show reliable endogenous expression and work well as positive controls for Western blot. For tissue samples, placenta, lung, and kidney express relatively high levels. ADAM-15 is upregulated in smooth muscle cells and endothelial cells during migration and wound healing, so these primary cultures can serve as functional positive controls. If your cell line shows no signal, consider stimulation with growth factors or use of an ADAM-15-transfected cell lysate as a reference standard.

Can this antibody detect the shed ectodomain of ADAM-15 in conditioned media?

ADAM-15 undergoes ectodomain shedding, releasing the extracellular portion into culture supernatants or extracellular fluids. Whether this antibody detects the shed ectodomain depends on the epitope location, which should be confirmed with the immunogen sequence. If the epitope resides within the metalloproteinase or disintegrin domains (extracellular), detection in concentrated conditioned media is possible. Concentrate serum-free conditioned media 10- to 20-fold using centrifugal filters before Western blot. If the epitope is within the cytoplasmic tail, only cell lysates will yield signal. Check immunogen details or contact us to confirm epitope mapping.

How should I store the ADAM-15 antibody and how long is it stable?

Store the antibody at -20°C in small aliquots to avoid repeated freeze-thaw cycles, which can reduce titer and increase aggregation. The antibody is supplied as a polyclonal rabbit serum or purified IgG in buffer containing carrier protein and preservative; check the product datasheet for exact formulation. Under these storage conditions, the antibody remains stable for at least 12 months from the date of receipt. For long-term storage beyond one year, -80°C is preferred. Once thawed, working aliquots can be kept at 4°C for up to one month if sodium azide is present. Do not store diluted antibody.

Why am I seeing multiple bands for ADAM-15 on my Western blot?

Multiple bands are common with ADAM-15 and reflect its biology. The protein exists as a full-length proform, a mature processed form after prodomain removal, and various shed or cleaved fragments. Heterogeneous glycosylation adds further complexity, producing a smeared or ladder-like appearance between 90-110 kDa for full-length forms. Lower molecular weight bands may represent the shed ectodomain, intracellular C-terminal fragments, or degradation products if protease inhibitors were insufficient during lysis. Always include a protease inhibitor cocktail in your lysis buffer. If bands persist, validate identity by including a blocking peptide control or testing lysate from ADAM-15 knockout cells.

Validation imagery coming soon

Western blot validation figures for RP-ADAM15 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

Also known as:

  • ADAM15
  • ADAM 15
  • Disintegrin and metalloproteinase domain-containing protein 15
  • Metalloprotease RGD disintegrin protein
  • Metalloproteinase-like
  • disintegrin-like
  • and cysteine-rich protein 15
  • MDC-15
  • Metargidin
  • EC 3.4.24.-
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →